InvestorsHub Logo
Followers 26
Posts 8775
Boards Moderated 0
Alias Born 07/11/2006

Re: None

Friday, 11/03/2017 5:43:33 PM

Friday, November 03, 2017 5:43:33 PM

Post# of 5907
AVEO is encouraged by the promising preliminary tolerability and activity results from the TiNivo trial, and believes that they begin to underscore the unique potential of tivozanib-immunotherapy combinations. The Company expects to present the results of the phase 2 portion of the TiNivo trial in the first half of 2018, and anticipates initiating additional combination studies in the next year.


Any posts are just an opinion and should not be taken as investment advice. Always do your own DD